A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview

Background: We sought to compare the benefits and safety of 6 biologics (abatacept, adalimumab, anakinra, etanercept, infliximab and rituximab) in patients with rheumatoid arthritis. Methods: In this network meta-analysis, we included all completed and updated Cochrane reviews on biologics for rheumatoid arthritis. We included data from all placebo-controlled trials that used standard dosing regimens. The major outcomes were benefit (defined as a 50% improvement in patient- and physician-reported criteria of the American College of Rheumatology [ACR50]) and safety (determined by the number of withdrawals related to adverse events). We used mixed-effects logistic regression to carry out an indirect comparison of the treatment effects between biologics. Results: Compared with placebo, biologics were associated with a clinically important higher ACR50 rate (odds ratio [OR] 3.35, 95% confidence interval [CI] 2.62–4.29) and a number needed to treat for benefit of 4 (95% CI 4–6). However, biologics were associated with more withdrawals related to adverse events (OR 1.39, 95% CI 1.13–1.71), with a number needed to treat for harm of 52 (95% CI 29–152). Anakinra was less effective than all of the other biologics, although this difference was statistically significant only for the comparison with adalimumab (OR 0.45, 95% CI 0.21–0.99) and etanercept (OR 0.34, 95% CI 0.14–0.81). Adalimumab, anakinra and infliximab were more likely than etanercept to lead to withdrawals related to adverse events (adalimumab OR 1.89, 95% CI 1.18–3.04; anakinra OR 2.05, 95% CI 1.27–3.29; and infliximab OR 2.70, 95% CI 1.43–5.26). Interpretation: Given the limitations of indirect comparisons, anakinra was less effective than adalimumab and etanercept, and etanercept was safer than adalimumab, anakinra and infliximab. This summary of the evidence will help physicians and patients to make evidence-based choices about biologics for the treatment of rheumatoid arthritis.

[1]  M. Suarez‐Almazor,et al.  Biologics for rheumatoid arthritis: an overview of Cochrane reviews , 2009, The Cochrane database of systematic reviews.

[2]  Jasvinder A Singh,et al.  Abatacept for rheumatoid arthritis. , 2009, The Cochrane database of systematic reviews.

[3]  A. Perdriger Infliximab in the treatment of rheumatoid arthritis , 2009, Biologics : targets & therapy.

[4]  J. Singh,et al.  Anakinra for rheumatoid arthritis. , 2009, The Cochrane database of systematic reviews.

[5]  M. Genovese,et al.  The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial , 2008, Annals of the rheumatic diseases.

[6]  M. Suarez‐Almazor,et al.  Biologics for rheumatoid arthritis , 2009 .

[7]  Michael J. Green,et al.  Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[8]  A. Oxman,et al.  Overviews of Reviews , 2008 .

[9]  F. Breedveld,et al.  Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial , 2008, The Lancet.

[10]  A. Alonso-Ruiz,et al.  Bmc Musculoskeletal Disorders Tumor Necrosis Factor Alpha Drugs in Rheumatoid Arthritis: Systematic Review and Metaanalysis of Efficacy and Safety , 2008 .

[11]  N. Miyasaka Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study , 2008, Modern rheumatology.

[12]  K. Lohr,et al.  Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis , 2008, Annals of Internal Medicine.

[13]  M. Dougados,et al.  Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate , 2007, Annals of the rheumatic diseases.

[14]  Y. Lee,et al.  Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis , 2008, Rheumatology International.

[15]  A. Brennan,et al.  PAR15 USING MIXED TREATMENT COMPARISONS AND METAREGRESSION TO PERFORM INDIRECT COMPARISONS TO ESTIMATE THE EFFICACY OF BIOLOGIC TREATMENTS IN RHEUMATOID ARTHRITIS , 2007 .

[16]  Yeong-Wook Song,et al.  A randomized, double‐blind, placebo‐controlled, phase III study of the human anti‐tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate , 2007 .

[17]  E. Yelin Work disability in rheumatic diseases , 2007, Current opinion in rheumatology.

[18]  David Moher,et al.  Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews , 2007, BMC medical research methodology.

[19]  V. Bykerk,et al.  Etanercept in the treatment of rheumatoid arthritis , 2007, Therapeutics and clinical risk management.

[20]  H. Bliddal,et al.  The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review , 2007, Scandinavian journal of rheumatology.

[21]  J. Kremer,et al.  Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial , 2006, Annals of the rheumatic diseases.

[22]  K. Lohr,et al.  The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. , 2006, The Journal of rheumatology.

[23]  Stanley B. Cohen,et al.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.

[24]  H. Genant,et al.  Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis , 2006, Annals of Internal Medicine.

[25]  P. Emery,et al.  The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. , 2006, Arthritis and rheumatism.

[26]  G G Koch,et al.  Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities , 2006, Annals of the rheumatic diseases.

[27]  B. Hernández-Cruz,et al.  Adalimumab for treating rheumatoid arthritis. , 2005, The Journal of rheumatology.

[28]  H. Okamoto Tumor necrosis factor inhibitors for rheumatoid arthritis. , 2006, The New England journal of medicine.

[29]  F. Breedveld,et al.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. , 2006, Arthritis and rheumatism.

[30]  M. Dougados,et al.  Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. , 2005, The New England journal of medicine.

[31]  A. Finset,et al.  Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7‐year study from the Oslo RA register , 2005, Scandinavian journal of rheumatology.

[32]  Alexander Fraser,et al.  Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-contro , 2005, Arthritis and rheumatism.

[33]  D. M. van der Heijde,et al.  Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. , 2004, Arthritis and rheumatism.

[34]  P. Emery,et al.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.

[35]  E. Keystone,et al.  Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. , 2004, Arthritis and rheumatism.

[36]  M. Genovese,et al.  Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. , 2004, Arthritis and rheumatism.

[37]  M. Dougados,et al.  Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed , 2004, Annals of the rheumatic diseases.

[38]  L. Moreland,et al.  A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate , 2004, Annals of the rheumatic diseases.

[39]  L. Klareskog,et al.  Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial , 2004, The Lancet.

[40]  H. Ascher-Svanum,et al.  Assessing the value of antipsychotics for treating schizophrenia , 2004, PharmacoEconomics.

[41]  V. Strand,et al.  Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). , 2003, The Journal of rheumatology.

[42]  M. Dougados,et al.  Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. , 2003, The New England journal of medicine.

[43]  G. Burmester,et al.  Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. , 2003, Arthritis and rheumatism.

[44]  M. Suarez‐Almazor,et al.  Number needed to treat (NNT): implication in rheumatology clinical practice , 2003, Annals of the rheumatic diseases.

[45]  M. Weisman,et al.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.

[46]  Stanley B. Cohen,et al.  Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. , 2002, Arthritis and rheumatism.

[47]  Stanley B. Cohen,et al.  Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.

[48]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[49]  N Breslow,et al.  Generalized linear mixed models for meta-analysis. , 1999, Statistics in medicine.

[50]  D. Furst,et al.  Etanercept Therapy in Rheumatoid Arthritis , 1999, Annals of Internal Medicine.

[51]  J. Kremer,et al.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.

[52]  D. Furst,et al.  Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. , 1999, Annals of internal medicine.

[53]  Z Domljan,et al.  Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. , 1998, Arthritis and rheumatism.

[54]  D. Whalley,et al.  Quality of life in rheumatoid arthritis. , 1997, British journal of rheumatology.

[55]  F. Arnett Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[56]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[57]  L. T. Swaim American Rheumatism Association , 1950 .